Article Text

Download PDFPDF
Clinical round-up
  1. Emily Chung1,
  2. Sophie Herbert2
  1. 1 Sexual Health and HIV, Mortimer Market Centre, London, UK
  2. 2 Department of Sexual Health, Ashwood Centre, Kettering, UK
  1. Correspondence to Dr Emily Chung, Sexual Health and HIV, Mortimer Market Centre, London 56273, UK; e.chung{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Weekends off efavirenz-based antiretroviral therapy (ART) in children and adolescents non-inferior to continuous therapy

BREATHER (BREaks in Adolescent and child Therapy using Efavirenz and two nRTIs) was an open-label, randomised, non-inferiority trial previously showing short-cycle therapy (SCT, 5 days on, 2 days off) was non-inferior at maintaining viral suppression with similar safety and resistance profiles, compared with continuous therapy (CT) at 48 weeks; Turkova et al 1 report the results from the extended additional 96 weeks of follow-up. Participants were eligible if 8–24 years old, virologically suppressed for at least a year on first-line efavirenz-based antiretroviral therapy (ART). The primary outcome was the proportion who had viral rebound by week 48, with secondary endpoints for the extended follow-up being viral rebound at any stage, viral suppression at 96 and 144 weeks, and adverse events. Ninety-nine participants were assigned to SCT and 100 to CT; 97 per arm consented to the extended follow-up. The median age was 14 years, 53% were male, 90% were vertically infected, and the median CD4 was 735x10^6/L. Sixteen from each arm had viral load >50 copies/mL by …

View Full Text


  • Competing interests None declared.

  • Provenance and peer review Commissioned; internally peer reviewed.